Ongoing Phase II and III studies in Philadelphia chromosome–positive adult acute lymphoblastic leukemia (ALL).
| Study group . | Study name . | Age range, y . | Study type . | Study questions . |
|---|---|---|---|---|
| Abbreviations: HSCT, hematopoietic stem cell transplantation; MUD, matched unrelated donor | ||||
| European Intergroup | EsPhALL | 1–17 | Randomized Phase II/III | Good-risk patients imatinib vs. no imatinib Poor-risk, all get imatinib. All get HSCT if donor available, includes umbilical cord |
| GRAALL (France) | GRAAPh02/2015 | 15–59 | Randomized Phase III | Hyper-CVAD/standard Imatinib vs. “imatinib-based” |
| EWALL (Pan-European) | EWALLPh | > 65 | Phase II | Dasatinib with low-dose chemotherapy. |
| GIMEMA (Italy) | LAL1205 | ≥15 | Phase II | Dasatinib as induction therapy. |
| GMALL (Germany) | Imatinib/MRD/01/01 | ≥15 | Phase II | Benefit of imatinib in induction. |
| GMALL (Germany) | GMALL STI1517- elderly 01/02 | ≥55 | Phase II | Single-agent imatinib effectiveness and tolerability. |
| JALSG (Japan) | Ph+ ALL2008 | 15–64 | Phase II | Intensified imatinib and chemotherapy during post-remission therapy. |
| MDACC | 2006-0478 | 18–64 | Phase II Phase II | Dasatinib with hyper-CVAD. Benefit of imatinib in induction. Evaluation of sib/MUD HSCT. Benefit of imatinib as post HSCT. Maintenance. |
| MRC/ECOG (UK/USA) | UKALLXII/ECOG 2993 | 15–65 | ||
| CALGB | CALGB 10001 | — | Phase II | Chemotherapy and imatinib followed by allogenic or autologous HSCT. |
| Study group . | Study name . | Age range, y . | Study type . | Study questions . |
|---|---|---|---|---|
| Abbreviations: HSCT, hematopoietic stem cell transplantation; MUD, matched unrelated donor | ||||
| European Intergroup | EsPhALL | 1–17 | Randomized Phase II/III | Good-risk patients imatinib vs. no imatinib Poor-risk, all get imatinib. All get HSCT if donor available, includes umbilical cord |
| GRAALL (France) | GRAAPh02/2015 | 15–59 | Randomized Phase III | Hyper-CVAD/standard Imatinib vs. “imatinib-based” |
| EWALL (Pan-European) | EWALLPh | > 65 | Phase II | Dasatinib with low-dose chemotherapy. |
| GIMEMA (Italy) | LAL1205 | ≥15 | Phase II | Dasatinib as induction therapy. |
| GMALL (Germany) | Imatinib/MRD/01/01 | ≥15 | Phase II | Benefit of imatinib in induction. |
| GMALL (Germany) | GMALL STI1517- elderly 01/02 | ≥55 | Phase II | Single-agent imatinib effectiveness and tolerability. |
| JALSG (Japan) | Ph+ ALL2008 | 15–64 | Phase II | Intensified imatinib and chemotherapy during post-remission therapy. |
| MDACC | 2006-0478 | 18–64 | Phase II Phase II | Dasatinib with hyper-CVAD. Benefit of imatinib in induction. Evaluation of sib/MUD HSCT. Benefit of imatinib as post HSCT. Maintenance. |
| MRC/ECOG (UK/USA) | UKALLXII/ECOG 2993 | 15–65 | ||
| CALGB | CALGB 10001 | — | Phase II | Chemotherapy and imatinib followed by allogenic or autologous HSCT. |